Your browser doesn't support javascript.
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
Collier, Ai-Ris Y; McMahan, Katherine; Yu, Jingyou; Tostanoski, Lisa H; Aguayo, Ricardo; Ansel, Jessica; Chandrashekar, Abishek; Patel, Shivani; Apraku Bondzie, Esther; Sellers, Daniel; Barrett, Julia; Sanborn, Owen; Wan, Huahua; Chang, Aiquan; Anioke, Tochi; Nkolola, Joseph; Bradshaw, Connor; Jacob-Dolan, Catherine; Feldman, Jared; Gebre, Makda; Borducchi, Erica N; Liu, Jinyan; Schmidt, Aaron G; Suscovich, Todd; Linde, Caitlyn; Alter, Galit; Hacker, Michele R; Barouch, Dan H.
  • Collier AY; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • McMahan K; Harvard Medical School, Boston, Massachusetts.
  • Yu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Tostanoski LH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Aguayo R; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Ansel J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Chandrashekar A; Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Patel S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Apraku Bondzie E; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Sellers D; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Barrett J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Sanborn O; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Wan H; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Chang A; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Anioke T; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Nkolola J; Harvard Medical School, Boston, Massachusetts.
  • Bradshaw C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Jacob-Dolan C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Feldman J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Gebre M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Borducchi EN; Harvard Medical School, Boston, Massachusetts.
  • Liu J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Schmidt AG; Harvard Medical School, Boston, Massachusetts.
  • Suscovich T; Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts.
  • Linde C; Harvard Medical School, Boston, Massachusetts.
  • Alter G; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Hacker MR; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
JAMA ; 325(23): 2370-2380, 2021 06 15.
Artigo em Inglês | MEDLINE | ID: covidwho-1287297
Informação semântica de SemMedBD (por NLM)
1. Lactation established in non-human animal PROCESS_OF Woman
Sujeito
Lactation established in non-human animal
Predicado
PROCESS_OF
Objeto
Woman
2. COVID-19 PROCESS_OF Woman
Sujeito
COVID-19
Predicado
PROCESS_OF
Objeto
Woman
3. COVID-19 Vaccines ADMINISTERED_TO Woman
Sujeito
COVID-19 Vaccines
Predicado
ADMINISTERED_TO
Objeto
Woman
4. Fever PROCESS_OF Pregnant Women
Sujeito
Fever
Predicado
PROCESS_OF
Objeto
Pregnant Women
5. Functional antibody studies DIAGNOSES Gravidity
Sujeito
Functional antibody studies
Predicado
DIAGNOSES
Objeto
Gravidity
6. Umbilical Cord Blood PART_OF Infant
Sujeito
Umbilical Cord Blood
Predicado
PART_OF
Objeto
Infant
7. Milk (body substance) LOCATION_OF Antibodie
Sujeito
Milk (body substance)
Predicado
LOCATION_OF
Objeto
Antibodie
8. Umbilical Cord Blood LOCATION_OF Antibodie
Sujeito
Umbilical Cord Blood
Predicado
LOCATION_OF
Objeto
Antibodie
9. Antibody Formation PROCESS_OF Woman
Sujeito
Antibody Formation
Predicado
PROCESS_OF
Objeto
Woman
10. Lactation established in non-human animal PROCESS_OF Woman
Sujeito
Lactation established in non-human animal
Predicado
PROCESS_OF
Objeto
Woman
11. COVID-19 PROCESS_OF Woman
Sujeito
COVID-19
Predicado
PROCESS_OF
Objeto
Woman
12. COVID-19 Vaccines ADMINISTERED_TO Woman
Sujeito
COVID-19 Vaccines
Predicado
ADMINISTERED_TO
Objeto
Woman
13. Fever PROCESS_OF Pregnant Women
Sujeito
Fever
Predicado
PROCESS_OF
Objeto
Pregnant Women
14. Functional antibody studies DIAGNOSES Gravidity
Sujeito
Functional antibody studies
Predicado
DIAGNOSES
Objeto
Gravidity
15. Umbilical Cord Blood PART_OF Infant
Sujeito
Umbilical Cord Blood
Predicado
PART_OF
Objeto
Infant
16. Milk (body substance) LOCATION_OF Antibodies, Neutralizing
Sujeito
Milk (body substance)
Predicado
LOCATION_OF
Objeto
Antibodies, Neutralizing
17. Umbilical Cord Blood LOCATION_OF Antibodies, Neutralizing
Sujeito
Umbilical Cord Blood
Predicado
LOCATION_OF
Objeto
Antibodies, Neutralizing
18. Antibody Formation PROCESS_OF Woman
Sujeito
Antibody Formation
Predicado
PROCESS_OF
Objeto
Woman
ABSTRACT
Importance Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on vaccine safety and immunogenicity in these populations are therefore limited.

Objective:

To evaluate the immunogenicity of COVID-19 messenger RNA (mRNA) vaccines in pregnant and lactating women, including against emerging SARS-CoV-2 variants of concern. Design, Setting, and

Participants:

An exploratory, descriptive, prospective cohort study enrolled 103 women who received a COVID-19 vaccine from December 2020 through March 2021 and 28 women who had confirmed SARS-CoV-2 infection from April 2020 through March 2021 (the last follow-up date was March 26, 2021). This study enrolled 30 pregnant, 16 lactating, and 57 neither pregnant nor lactating women who received either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines and 22 pregnant and 6 nonpregnant unvaccinated women with SARS-CoV-2 infection. Main Outcomes and

Measures:

SARS-CoV-2 receptor binding domain binding, neutralizing, and functional nonneutralizing antibody responses from pregnant, lactating, and nonpregnant women were assessed following vaccination. Spike-specific T-cell responses were evaluated using IFN-γ enzyme-linked immunospot and multiparameter intracellular cytokine-staining assays. Humoral and cellular immune responses were determined against the original SARS-CoV-2 USA-WA1/2020 strain as well as against the B.1.1.7 and B.1.351 variants.

Results:

This study enrolled 103 women aged 18 to 45 years (66% non-Hispanic White) who received a COVID-19 mRNA vaccine. After the second vaccine dose, fever was reported in 4 pregnant women (14%; SD, 6%), 7 lactating women (44%; SD, 12%), and 27 nonpregnant women (52%; SD, 7%). Binding, neutralizing, and functional nonneutralizing antibody responses as well as CD4 and CD8 T-cell responses were present in pregnant, lactating, and nonpregnant women following vaccination. Binding and neutralizing antibodies were also observed in infant cord blood and breast milk. Binding and neutralizing antibody titers against the SARS-CoV-2 B.1.1.7 and B.1.351 variants of concern were reduced, but T-cell responses were preserved against viral variants. Conclusion and Relevance In this exploratory analysis of a convenience sample, receipt of a COVID-19 mRNA vaccine was immunogenic in pregnant women, and vaccine-elicited antibodies were transported to infant cord blood and breast milk. Pregnant and nonpregnant women who were vaccinated developed cross-reactive antibody responses and T-cell responses against SARS-CoV-2 variants of concern.
Assuntos

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de documento: Artigo Assunto principal: Sangue Fetal / Imunogenicidade da Vacina / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Leite Humano / Anticorpos Antivirais Tipo de estudo: Estudo observacional / Fatores de risco Idioma: Inglês Revista: JAMA Aspecto clínico: Etiologia / Prognóstico Ano de publicação: 2021

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de documento: Artigo Assunto principal: Sangue Fetal / Imunogenicidade da Vacina / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Leite Humano / Anticorpos Antivirais Tipo de estudo: Estudo observacional / Fatores de risco Idioma: Inglês Revista: JAMA Aspecto clínico: Etiologia / Prognóstico Ano de publicação: 2021
...